Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route
/in Dendritic Cells, International Publications, Malignant MelanomaAttacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines
/in International Publications, Newcastle Disease VirusImproved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
/in Dendritic Cells, Exosome, Glioblastoma, Hypernephroma, International PublicationsTwo phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
/in Breast Cancer, Hyperthermia, International PublicationsThe effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.
/in Dendritic Cells, Hyperthermia, International PublicationsResponse of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.
/in Hyperthermia, International Publications, Prostate CancerA phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
/in Dendritic Cells, Hypernephroma, International PublicationsPharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
/in International Publications, Newcastle Disease Virus, NSCLCSorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
/in Hepatocellular Carcinoma, Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer